Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation

Postimplant Phosphodiesterase Type 5 Inhibitors Use Is Associated With Lower Rates of Thrombotic Events After Left Ventricular Assist Device Implantation

Background Left ventricular assist device (LVAD) thrombosis is clinically devastating and impacts the cost effectiveness of LVAD therapy for advanced heart failure. Anticoagulation and antiplatelet therapies represent the standard of care to mitigate LVAD thrombosis. Phosphodiesterase type 5 inhibit...

Full description

Bibliographic Details
Main Authors: Andrew Xanthopoulos, Konstantinos Tryposkiadis, Filippos Triposkiadis, Kiyotaka Fukamachi, Edward G. Soltesz, James B. Young, Kathy Wolski, Eugene H. Blackstone, Randall C. Starling
Format: Article
Language:English
Published: Wiley 2020-07-01
Series:Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Subjects:
complications
heart failure
pharmacology
sildenafil
Online Access:https://www.ahajournals.org/doi/10.1161/JAHA.119.015897

Internet

https://www.ahajournals.org/doi/10.1161/JAHA.119.015897

Similar Items